SCHEMBL2175628

SCHEMBL2175628

COc1cc(Oc2ccnc3ccc(F)cc23)ccc1C(C)C(=O)OC(C)(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 3/20 0.50
KDR P35968 10/20 0.48
PDGFRA P16234 9/20 0.48
PDGFRB P09619 3/20 0.48
AXL P30530 5/20 0.48
FGFR2 P21802 2/20 0.48
KIT P10721 2/20 0.48
CSF1R P07333 1/20 0.47
DDR2 Q16832 2/20 0.44
AURKA O14965 1/20 0.44
RIPK2 O43353 1/20 0.44
ABCB11 O95342 1/20 0.44
ABL1 P00519 1/20 0.44
EGFR P00533 1/20 0.44
ERBB2 P04626 1/20 0.44
NTRK1 P04629 1/20 0.44
LCK P06239 1/20 0.44
PGR P06401 1/20 0.44
LYN P07948 1/20 0.44
RET P07949 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2175230 0.87 KDR (0.53) METKDRPDGFRAPDGFRBAXL
SCHEMBL5598854 0.86 CCNC (0.44) METKDRPDGFRAPDGFRBAXL
SCHEMBL2174999 0.80 PDGFRB (0.61) METKDRPDGFRAPDGFRBAXL
SCHEMBL2172121 0.77 PDGFRB (0.71) METKDRPDGFRAPDGFRBAXL
SCHEMBL2173726 0.75 KDR (0.73) KDRPDGFRAPDGFRBAXLFGFR2
SCHEMBL2176270 0.74 PDGFRB (0.66) METKDRPDGFRAPDGFRBAXL
SCHEMBL4710074 0.74 KDR (0.46) METKDRPDGFRAPDGFRBAXL
SCHEMBL2175020 0.72 PDGFRB (0.61) METKDRPDGFRAPDGFRBAXL
SCHEMBL5598508 0.72 CCNC (0.48) METKDRPDGFRAPDGFRBAXL
SCHEMBL11727493 0.71 GAK (0.61) KDRPDGFRAPDGFRBAXLFGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973164-B2 Quinoline derivatives ASTRAZENECA AB (SE) 2011-07-05 US disclosed
US-20090076074-A1 QUINOLINE DERIVATIVES ASTRAZENECA AB (SE) 2009-03-19 US disclosed
EP-1994025-A1 QUINOLINE DERIVATIVES AstraZeneca AB (SE) 2008-11-26 EP disclosed
WO-2007099326-A1 QUINOLINE DERIVATIVES ASTRAZENECA AB (SE) 2007-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076074-A1 QUINOLINE DERIVATIVES RECQL, NQO2, CCNA1 MET 3334/4885KDR 2277/4885PDGFRA 1432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.